IDL Biotech AB
IDL Diagnostics AB is a Swedish in vitro diagnostics company that develops and commercializes point-of-care and laboratory IVD tests for oncology and infectious disease, serving hospitals, clinics, and laboratories across Europe, Southeast Asia, China, Africa, and the Middle East through direct sales, regional distributors, and a long-term OEM licensing partnership with Beckman Coulter Diagnostics.
- Company typePublic
- Founded1988
- HeadquartersBromma, Sweden
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What IDL Biotech AB does
IDL Biotech AB, operating as IDL Diagnostics AB, is a Swedish in vitro diagnostics (IVD) company headquartered in Bromma, Sweden, that develops and commercializes diagnostic tests for oncology and infectious disease applications. The company's product portfolio includes UBC Rapid, a point-of-care urine-based test for bladder cancer detection and monitoring that can be used in doctors' offices without specialized laboratory equipment; TUBEX TF, a rapid in vitro diagnostic test for acute typhoid fever caused by Salmonella typhi; and TK 210 ELISA, an immunoassay measuring Thymidine Kinase 1 as a cell proliferation biomarker for therapy response monitoring in cancer patients, validated for use on automated laboratory platforms. The firm serves hospitals, clinics, oncology practices, and clinical laboratories, and operates across Sweden, Southeast Asia (Indonesia, Philippines), China, Kenya, and the UAE. IDL Biotech generates revenue through one-time sales of diagnostic products to healthcare providers and laboratories, transaction-based revenue from regional distribution partners in international markets, and licensing royalties from its long-standing OEM partnership with Beckman Coulter Diagnostics, which distributes the company's manual ELISA and radioimmunoassay tumor marker product lines globally. Listed on NASDAQ First North Growth Market and employing 11-50 staff, the company is a self-described smaller player in a large IVD market, pursuing growth through geographic expansion, distributor partnerships, and OEM licensing rather than direct global commercialization.
IDL Biotech AB firmographics
Firmographics- Name
- IDL Biotech AB
- Legal name
- IDL Diagnostics AB
- Website
- https://idlbiotech.com
- Company type
- Public
- Founded year
- 1988
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- IDL Diagnostics AB is a Swedish in vitro diagnostics company that develops and commercializes point-of-care and laboratory IVD tests for oncology and infectious disease, serving hospitals, clinics, and laboratories across Europe, Southeast Asia, China, Africa, and the Middle East through direct sales, regional distributors, and a long-term OEM licensing partnership with Beckman Coulter Diagnostics.
- Ownership category
- akta.pro rank
IDL Biotech AB industry classification
Industry- Product category
- In Vitro Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835)
- akta.pro primary industry
- IVD Reagents, Assay Kits & Consumables (Non-instrument) (HLAHAAAM)
- akta.pro secondary industries
- Clinical Chemistry & Immunoassay Laboratories (HLAFAMAB), Urinalysis & Routine Screening Diagnostics (HLAHAAAG)
Keywords
Where IDL Biotech AB is headquartered
LocationHeadquarters
- HQ city
- Bromma
- HQ country
- Sweden
- HQ region
- Europe
Offices1 record
Markets served
IDL Biotech AB business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain
Revenue model
- Diagnostic Product Sales: Sale of IVD diagnostic tests including UBC Rapid, TUBEX TF, and TK 210 ELISA to healthcare providers, laboratories, and through distribution partners.
- Licensing Royalties: Licensing agreements with strategic partners such as Beckman Coulter Diagnostics for tumor marker product lines (manual ELISA and radioimmunoassay platforms).
- Marketplace/ Distribution Revenue: Revenue from distribution network across Southeast Asia and China through regional distributors.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels4 records
IDL Biotech AB product offering
Product offeringCore offering
IDL Biotech AB develops and commercializes in vitro diagnostic (IVD) tests for oncology and bacteriology, including the UBC Rapid point-of-care urine test for bladder cancer detection and monitoring, TUBEX TF rapid test for acute typhoid fever, and the TK 210 ELISA kit for measuring thymidine kinase 1 (TK1) to monitor cancer therapy response. The company also licenses manual ELISA and radioimmunoassay tumor marker product lines to Beckman Coulter Diagnostics for global distribution.
Product overview
IDL Diagnostics (formerly AroCell) is a Swedish in vitro diagnostics company offering a portfolio of IVD tests for oncology and bacteriology applications. The core product portfolio includes: UBC® Rapid for bladder cancer detection, TUBEX® TF for typhoid fever detection, and TK 210 ELISA for cell proliferation monitoring in cancer therapy. The company also licenses tumor marker products to strategic partners such as Beckman Coulter Diagnostics. The products are designed for point-of-care use (UBC Rapid, TUBEX TF) and laboratory settings (TK 210 ELISA), delivering clinical information for disease detection, diagnosis, and monitoring.
Differentiator
Problem solved
Functional benefit
Brands
- UBC Rapid: Point-of-care test for bladder cancer detection and monitoring.
- TUBEX TF
- TK 210 ELISA
Products and services
- UBC Rapid A point-of-care test designed for aid in the diagnosis and monitoring of bladder cancer. It provides rapid detection in a doctor's-office setting, supporting clinical decision-making without requiring specialized laboratory equipment.
- TUBEX TF A rapid and sensitive in vitro diagnostic test for the detection of acute typhoid fever caused by Salmonella typhi, intended for use in healthcare facilities and laboratories.
- TK 210 ELISA An ELISA kit used for measuring thymidine kinase 1 (TK1) as a cell proliferation biomarker for therapy response in subjects with various forms of cancer, including several solid tumors. Validated for use on automated platforms.
- Tumor markers licensed to strategic partners Manual ELISA tumor marker product lines licensed to Beckman Coulter Diagnostics, including tumor marker products on the manual radioimmunoassay platform for broader global distribution and automated assay development.
- Quality Assurance products Quality assurance products supporting the company's IVD test portfolio, delivering high-value clinical information for disease detection.
Quantifiable outcome
- UBC Rapid can reduce the number of cystoscopies necessary in bladder cancer patients, enabling cost-effective follow-up
Companies that use IDL Biotech AB
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles3 records
IDL Biotech AB technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
IDL Biotech AB partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Beckman Coulter DiagnosticscoreLong-term strategic partnership where Beckman Coulter licensed IDL Biotech's manual ELISA tumor marker product line. IDL Biotech focuses on rapid diagnostic tests and automated assays of its tumor markers while licensing the manual platform to Beckman Coulter for expanded market reach.
- Beckman Coulter DiagnosticscoreLicense agreement for IDL Biotech's tumor marker product line on the manual radioimmunoassay platform to Beckman Coulter Diagnostics, enabling broader global distribution of the product line.
- concilminorCo-exhibition partnership at WHX Labs Dubai (February 2026) at Booth SA.A55, where both companies exhibited together as partners in the diagnostics space.
- SISP (Sweden-Indonesia Sustainability Partnership)minorParticipation in Sweden-Indonesia Sustainability Partnership 2025 to strengthen presence in Indonesia and build sustainable business relationships in the region.
- Southeast Asian DistributorscoreDistribution partnerships established in Indonesia and Philippines for sales and distribution of IDL Diagnostics products including UBC Rapid, TUBEX TF, and TK 210 ELISA.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
IDL Biotech AB competitors and assessment
Company assessmentBroad incumbents
- Sekisui Diagnostics: Global diagnostics company offering clinical chemistry and immunoassay products, including rapid diagnostic tests. Comparable in offering both IVD reagents and rapid POC tests, though operating at much larger scale with broader menu.
- Bio-Rad Laboratories: Global life science and clinical diagnostics company offering ELISA kits, immunoassays, and quality controls. Comparable in offering ELISA-based diagnostic kits (like TK 210 ELISA) and quality assurance products serving clinical and research laboratories.
- Meridian Bioscience: US-based diagnostics company manufacturing diagnostic test kits for infectious diseases (including enteric diseases like typhoid). Comparable product categories (infectious disease diagnostics, immunoassays) though larger and broader portfolio than IDL.
- QuidelOrtho: Major diagnostics company producing rapid immunoassays and clinical chemistry products. Comparable in offering rapid point-of-care diagnostic tests and laboratory immunoassays, though operating globally with significantly broader product portfolio.
Direct peers
- Trinity Biotech: Ireland-based diagnostics company developing and manufacturing diagnostic test kits for infectious diseases and clinical chemistry. Comparable as a small/mid-cap IVD product company selling through distribution networks with both infectious disease and clinical diagnostic offerings.
- Oncocyte: US-based diagnostics company developing blood-based and urine-based cancer diagnostic tests, including bladder cancer detection (DetermaRx, VitaGraft). Comparable in its focus on oncology diagnostics for therapy monitoring and disease detection, serving oncology and urology markets.
- Pacific Edge Diagnostics: New Zealand-based diagnostics company focused on bladder cancer detection via urinary biomarker tests (Cxbladder). Directly comparable to IDL's UBC Rapid point-of-care bladder cancer test, serving the same urology and oncology customer segments with non-invasive diagnostics.
Emerging players
- Fujirebio: Japanese diagnostics company specializing in immunoassays and tumor markers, including cancer diagnostics. Comparable in focus on tumor marker and cancer biomarker diagnostics, with overlap in ELISA-based oncology assay offerings.
Market position
Strengths4 records
Weaknesses1 record
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
IDL Biotech AB social profiles
Digital presenceIDL Biotech AB financial estimates
Financial estimateRevenue estimate
Valuation estimate
IDL Biotech AB leadership team
Management profileNumber of profiles
Profiles4 records
IDL Biotech AB funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IDL Biotech AB M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IDL Biotech AB
What does IDL Biotech AB do?
IDL Biotech AB develops and commercializes in vitro diagnostic (IVD) tests for oncology and bacteriology, including the UBC Rapid point-of-care urine test for bladder cancer detection and monitoring, TUBEX TF rapid test for acute typhoid fever, and the TK 210 ELISA kit for measuring thymidine kinase 1 (TK1) to monitor cancer therapy response. The company also licenses manual ELISA and radioimmunoassay tumor marker product lines to Beckman Coulter Diagnostics for global distribution.
Is IDL Biotech AB a public or private company?
IDL Biotech AB is a public company. It is classified as public and is currently operating.
When was IDL Biotech AB founded?
IDL Biotech AB was founded in 1988. It employs 11 to 50 people.
Where is IDL Biotech AB based?
IDL Biotech AB is headquartered in Bromma, Sweden, in the Europe region.
How does IDL Biotech AB make money?
Three revenue lines are on record. Diagnostic Product Sales are the primary driver. The others are licensing Royalties and marketplace/ Distribution Revenue.
Who are IDL Biotech AB's main competitors?
Broad incumbents on record are Sekisui Diagnostics, Bio-Rad Laboratories, Meridian Bioscience and QuidelOrtho. Direct peers are Trinity Biotech, Oncocyte and Pacific Edge Diagnostics. Fujirebio is listed as an emerging player.
Does IDL Biotech AB have an API?
No public API is recorded for IDL Biotech AB.
What industry is IDL Biotech AB in?
IDL Biotech AB's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAHAAAM, IVD Reagents, Assay Kits & Consumables (Non-instrument), with a secondary code of HLAFAMAB, Clinical Chemistry & Immunoassay Laboratories. Its NAICS code is 325413 and its SIC code is 2835.